NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis $76.99 0.00 (0.00%) As of 08/27/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Forte Biosciences Stock (NASDAQ:FBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Forte Biosciences alerts:Sign Up Key Stats Today's Range$76.99▼$76.9950-Day Range$18.15▼$76.9952-Week Range$10.11▼$77.20VolumeN/AAverage Volume1.86 million shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice Target$71.67Consensus RatingHold Company Overview Forte Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions. The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis. FB-401 has shown promise in early studies for reducing inflammation and improving barrier function, and is currently being evaluated in Phase 2 clinical trials. In addition to atopic dermatitis, Forte is exploring pipeline opportunities in rare genetic skin conditions such as epidermolysis bullosa, where reinforcing the skin’s protective barrier is a critical unmet need. Forte Biosciences conducts clinical research across North America and Europe, collaborating with academic institutions and patient advocacy groups to accelerate development timelines. The company’s management team comprises professionals with extensive experience in biotechnology R&D, regulatory affairs, and commercial strategy, positioning Forte to translate scientific discoveries into potential therapeutic options for patients with chronic and rare skin disorders.AI Generated. May Contain Errors. Read More Forte Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreFBRX MarketRank™: Forte Biosciences scored higher than 28% of companies evaluated by MarketBeat, and ranked 796th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingForte Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.Downside RiskForte Biosciences has a consensus price target of $71.67, representing about 6.9% downside from its current price of $76.99.Amount of Analyst CoverageForte Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Forte Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Forte Biosciences are expected to decrease in the coming year, from ($4.27) to ($4.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -16.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -16.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 8.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Forte Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.04% of the float of Forte Biosciences has been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 1.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently decreased by 14.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.80 News SentimentForte Biosciences has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Forte Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for FBRX on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.40% of the stock of Forte Biosciences is held by insiders.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Forte Biosciences' insider trading history. Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FBRX Stock News HeadlinesForte Biosciences Completed Take-Private Merger and DelistingAugust 29 at 10:18 AM | theglobeandmail.comForte Biosciences (NASDAQ:FBRX) Rating Increased to Sell at Wall Street ZenAugust 29 at 1:11 AM | americanbankingnews.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.August 30 at 1:00 AM | Porter & Company (Ad)Argenx Completes Acquisition of Forte BiosciencesAugust 27 at 5:34 PM | finance.yahoo.comAnalysts Set Forte Biosciences, Inc. (NASDAQ:FBRX) Price Target at $72.50August 20, 2026 | americanbankingnews.comHedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte BiosciencesAugust 11, 2026 | insidermonkey.comForte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRXAugust 11, 2026 | businesswire.comFBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its ShareholdersAugust 8, 2026 | businesswire.comSee More Headlines FBRX Stock Analysis - Frequently Asked Questions How have FBRX shares performed this year? Forte Biosciences' stock was trading at $27.27 at the start of the year. Since then, FBRX shares have increased by 182.3% and is now trading at $76.99. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) issued its earnings results on Wednesday, August, 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.03. When did Forte Biosciences IPO? Forte Biosciences (FBRX) raised $94 million in an IPO on Thursday, April 13th 2017. The company issued 8,500,000 shares at a price of $10.00-$12.00 per share. Who are Forte Biosciences' major shareholders? Forte Biosciences' top institutional shareholders include AWM Investment Company Inc. (1.60%), Wellington Management Group LLP (0.32%), Bank of New York Mellon Corp (0.29%) and California State Teachers Retirement System (0.03%). Insiders that own company stock include Paul A Wagner and Antony A Riley. View institutional ownership trends. How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forte Biosciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), PayPal (PYPL), Qualcomm (QCOM), Avino Silver & Gold Mines (ASM), Meta Platforms (META) and Zoom Communications (ZM). Company Calendar Last Earnings8/12/2026Today8/30/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 FBRX's financial health is in the Green zone, according to TradeSmith. FBRX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FBRX CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees5Year Founded2001Price Target and Rating Average Price Target for Forte Biosciences$71.67 High Price Target$77.00 Low Price Target$61.00 Potential Upside/Downside-6.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($4.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-94.82% Return on Assets-77.68% Debt Debt-to-Equity RatioN/A Current Ratio10.01 Quick Ratio10.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.66 per share Price / Book8.89Miscellaneous Outstanding Shares21,229,000Free Float20,295,000Market Cap$1.63 billion OptionableOptionable Beta2.62 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:FBRX) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredHe called Apple then saw 12,000%+ gains. Now he's pointing at THIS.In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThese 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAIElon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
